Clinical endpoints for respiratory syncytial virus prophylaxis trials in infants and children in high-income and middle-income countries

Pediatric Infectious Disease Journal

Volumn 34, Issue 10, 2015, Pages 1086-1092

  Simoes, Eric A F ^a,b   Carbonell Estrany, Xavier ^c   Guilbert, Theresa ^d   Mansbach, Jonathan M ^e   Piedra, Pedro A ^f   Ramilo, Octavio ^g   Welliver, Robert ^h  

^a Children's Hospital Colorado   (United States)

^b Global Health and Health Disparities   (United States)

^c HOSPITAL CLÍNIC   (Spain)

^d CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

^f BAYLOR COLLEGE OF MEDICINE   (United States)

^g OHIO STATE UNIVERSITY   (United States)

^h UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

Burden; Epidemiology; Monoclonal antibodies; Prevention; Vaccines

Indexed keywords

ANTIBIOTIC PROPHYLAXIS; ARTICLE; ASTHMA; CHILD; CLINICAL FEATURE; CONSENSUS; DEVELOPED COUNTRY; DEVELOPING COUNTRY; EMERGENCY WARD; HEALTH CARE COST; HEALTH CARE PRACTICE; HOSPITALIZATION; HUMAN; HUMAN RESPIRATORY SYNCYTIAL VIRUS; INFANT; INTENSIVE CARE UNIT; OUTPATIENT; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL VIRUS INFECTION; RISK REDUCTION; WHEEZING; ABNORMAL RESPIRATORY SOUND; AMBULATORY CARE; ECONOMICS; PRESCHOOL CHILD; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME;

ANTIVIRUS AGENT; MONOCLONAL ANTIBODY;

AMBULATORY CARE; ANTIBIOTIC PROPHYLAXIS; ANTIBODIES, MONOCLONAL; ANTIVIRAL AGENTS; CHILD, PRESCHOOL; HOSPITALIZATION; HUMANS; INFANT; RESPIRATORY SOUNDS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; TREATMENT OUTCOME;

EID: 84942043396     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0000000000000813     Document Type: Article

References (83)

1. Hall CB, Weinberg GA, Iwane MK, et al. The burden of respiratory syncyt-ial virus infection in young children. N Engl J Med. 2009;360:588-598.
2. Glezen W P, Taber LH, Frank AL, et al. Risk of primary infection and reinfection with respiratory syncytial virus. Am J Dis Child. 1986;140:543-546.
3. Nair H, Brooks WA, Katz M, et al. Global burden of respiratory infections due to seasonal infuenza in young children: a systematic review and meta-analysis. Lancet. 2011;378:1917-1930.
4. Shay DK, Holman RC, Newman RD, et al. Bronchiolitis-associated hospi-talizations among US children, 1980-1996. JAMA. 1999;282:1440-1446.
5. Langley JM, LeBlanc JC, Smith B, et al. Increasing incidence of hospitali-zation for bronchiolitis among Canadian children, 1980-2000. J Infect Dis. 2003;188:1764-1767.
6. Boyce TG, Mellen BG, Mitchel EF Jr, et al. Rates of hospitalization for respiratory syncytial virus infection among children in medicaid. J Pediatr. 2000;137:865-870.
7. Holman RC, Curns AT, Cheek JE, et al. Respiratory syncytial virus hospital-izations among American Indian and Alaska Native infants and the general United States infant population. Pediatrics. 2004;114:e437-e444.
8. Zhou H, Thompson W W, Viboud CG, et al. Hospitalizations associated with infuenza and respiratory syncytial virus in the United States, 1993-2008. Clin Infect Dis. 2012;54:1427-1436.
9. Leader S, Kohlhase K. Recent trends in severe respiratory syncytial virus (RSV) among US infants, 1997 to 2000. J Pediatr. 2003;143(5 Suppl): S127-S132.
10. Hasegawa K, Tsugawa Y, Brown DF, et al. Trends in bronchiolitis hospitali-zations in the United States, 2000-2009. Pediatrics. 2013;132:28-36.
11. Stockman LJ, Curns AT, Anderson LJ, et al. Respiratory syncytial virus-associated hospitalizations among infants and young children in the United States, 1997-2006. Pediatr Infect Dis J. 2012;31:5-9.
12. Weinberger DM, Klugman K P, Steiner CA, et al. Association between respiratory syncytial virus activity and pneumococcal disease in infants: a time series analysis of US hospitalization data. PLoS Med. 2015;12:e1001776.
13. Iwane MK, Edwards KM, Szilagyi PG, et al; New Vaccine Surveillance Network. Population-based surveillance for hospitalizations associated with respiratory syncytial virus, infuenza virus, and parainfuenza viruses among young children. Pediatrics. 2004;113:1758-1764.
14. Fjaerli HO, Farstad T, Bratlid D. Hospitalisations for respiratory syncytial virus bronchiolitis in Akershus, Norway, 1993-2000: a population-based retrospective study. BMC Pediatr. 2004;4:25.
15. Forster J, Ihorst G, Rieger CH, et al. Prospective population-based study of viral lower respiratory tract infections in children under 3 years of age (the PRI.DE study). Eur J Pediatr. 2004;163:709-716.
16. Nicholson KG, McNally T, Silverman M, et al. Rates of hospitalisation for infuenza, respiratory syncytial virus and human metapneumovirus among infants and young children. Vaccine. 2006;24:102-108.
17. van Gageldonk-Lafeber AB, Heijnen ML, Bartelds AI, et al. A case-control study of acute respiratory tract infection in general practice patients in The Netherlands. Clin Infect Dis. 2005;41:490-497.
18. Eriksson M, Bennet R, Rotzén-Ostlund M, et al. Population-based rates of severe respiratory syncytial virus infection in children with and without risk factors, and outcome in a tertiary care setting. Acta Paediatr. 2002;91: 593-598.
19. Mansbach JM, McAdam AJ, Clark S, et al. Prospective multicenter study of the viral etiology of bronchiolitis in the emergency department. Acad Emerg Med. 2008;15:111-118.
20. Bourgeois FT, Valim C, McAdam AJ, et al. Relative impact of infuenza and respiratory syncytial virus in young children. Pediatrics. 2009;124: e1072-e1080.
21. American Academy of Pediatrics Subcommittee on D, Management of B. Diagnosis and management of bronchiolitis. Pediatrics. 2006;118: 1774-1793.
22. Hall CB, Simoes EA, Anderson LJ. Clinical and epidemiologic features of respiratory syncytial virus. Curr Top Microbiol Immunol. 2013;372:39-57.
23. Howard TS, Hoffman LH, Stang PE, et al. Respiratory syncytial virus pneumonia in the hospital setting: length of stay, charges, and mortality. J Pediatr. 2000;137:227-232.
24. Shay DK, Holman RC, Roosevelt GE, et al. Bronchiolitis-associated mortality and estimates of respiratory syncytial virus-associated deaths among US children, 1979-1997. J Infect Dis. 2001;183:16-22.
25. Thompson WW, Shay DK, Weintraub E, et al. Mortality associated with infuenza and respiratory syncytial virus in the United States. JAMA. 2003;289:179-186.
26. Byington CL, Wilkes J, Korgenski K, et al. Respiratory syncytial virus-associated mortality in hospitalized infants and young children. Pediatrics. 2015;135:e24-e31.
27. Wong KK, Jain S, Blanton L, et al. Infuenza-associated pediatric deaths in the United States, 2004-2012. Pediatrics. 2013;132:796-804.
28. Régnier SA. Respiratory syncytial virus immunization program for the United States: impact of performance determinants of a theoretical vaccine. Vaccine. 2013;31:4347-4354.
29. Kuehni CE, Spycher BD, Silverman M. Causal links between RSV infection and asthma: no clear answers to an old question. Am J Respir Crit Care Med. 2009;179:1079-1080.
30. Beigelman A, Bacharier LB. The role of early life viral bronchiolitis in the inception of asthma. Curr Opin Allergy Clin Immunol. 2013;13:211-216.
31. Sigurs N, Bjarnason R, Sigurbergsson F, et al. Asthma and immunoglobu-lin E antibodies after respiratory syncytial virus bronchiolitis: a prospective cohort study with matched controls. Pediatrics. 1995;95:500-505.
32. Stein RT, Sherrill D, Morgan WJ, et al. Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years. Lancet. 1999;354:541-545.
33. Jackson DJ, Gangnon RE, Evans MD, et al. Wheezing rhinovirus illnesses in early life predict asthma development in high-risk children. Am J Respir Crit Care Med. 2008;178:667-672.
34. Sigurs N, Aljassim F, Kjellman B, et al. Asthma and allergy patterns over 18 years after severe RSV bronchiolitis in the frst year of life. Thorax. 2010;65:1045-1052.
35. Régnier SA, Huels J. Association between respiratory syncytial virus hospi-talizations in infants and respiratory sequelae: systematic review and meta-analysis. Pediatr Infect Dis J. 2013;32:820-826.
36. Dharmage SC, Erbas B, Jarvis D, et al. Do childhood respiratory infections continue to infuence adult respiratory morbidity? Eur Respir J. 2009;33:237-244.
37. Wenzel SE, Gibbs RL, Lehr M V, et al. Respiratory outcomes in high-risk children 7 to 10 years after prophylaxis with respiratory syncytial virus immune globulin. Am J Med. 2002;112:627-633.
38. Simões EA, Groothuis JR, Carbonell-Estrany X, et al; Palivizumab Long-Term Respiratory Outcomes Study Group. Palivizumab prophylaxis, respiratory syncytial virus, and subsequent recurrent wheezing. J Pediatr. 2007;151:34-42, 42.e1.
39. Simões EA, Carbonell-Estrany X, Rieger CH, et al; Palivizumab Long-Term Respiratory Outcomes Study Group. The effect of respiratory syncytial virus on subsequent recurrent wheezing in atopic and nonatopic children. J Allergy Clin Immunol. 2010;126:256-262.
40. Yoshihara S, Kusuda S, Mochizuki H, et al; C-CREW Investigators. Effect of palivizumab prophylaxis on subsequent recurrent wheezing in preterm infants. Pediatrics. 2013;132:811-818.
41. Blanken MO, Rovers MM, Molenaar JM, et al; Dutch RSV Neonatal Network. Respiratory syncytial virus and recurrent wheeze in healthy pre-term infants. N Engl J Med. 2013;368:1791-1799.
42. Kim H W, Arrobio JO, Brandt CD, et al. Epidemiology of respiratory syncyt-ial virus infection in Washington, D.C. I. Importance of the virus in different respiratory tract disease syndromes and temporal distribution of infection. Am J Epidemiol. 1973;98:216-225.
43. Ogra PL. Respiratory syncytial virus: the virus, the disease and the immune response. Paediatr Respir Rev. 2004;5 (Suppl A):S119-S126.
44. Hall CB. The burgeoning burden of respiratory syncytial virus among children. Infect Disord Drug Targets. 2012;12:92-97.
45. Choudhuri JA, Ogden LG, Ruttenber AJ, et al. Effect of altitude on hospitalizations for respiratory syncytial virus infection. Pediatrics. 2006;117:349-356.
46. Wright M, Piedimonte G. Respiratory syncytial virus prevention and therapy: past, present, and future. Pediatr Pulmonol. 2011;46:324-347.
47. García CG, Bhore R, Soriano-Fallas A, et al. Risk factors in children hospitalized with RSV bronchiolitis versus non-RSV bronchiolitis. Pediatrics. 2010;126:e1453-e1460.
48. Ralston S, Hill V. Incidence of apnea in infants hospitalized with respiratory syncytial virus bronchiolitis: a systematic review. J Pediatr. 2009;155:728-733.
49. Schroeder AR, Mansbach JM. Recent evidence on the management of bron-chiolitis. Curr Opin Pediatr. 2014;26:328-333.
50. RespiGam [package insert]. Gaithersburg MD: Medimmune Inc.; 1996.
51. American Academy of Pediatrics Committee on Infectious Diseases, Committee on Fetus and Newborn. Respiratory syncytial virus immune globulin intravenous: indications for use. Pediatrics 1997; 99: 645-50.
52. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2002/palimed102302LB.pdf, 2015. Accessed May 7, 2015.
53. Group TPS. Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. Pediatrics 1997;99:93-9.
54. Feltes TF, Cabalka AK, Meissner HC, et al; Cardiac Synagis Study Group. Palivizumab prophylaxis reduces hospitalization due to respiratory syncy-tial virus in young children with hemodynamically signifcant congenital heart disease. J Pediatr. 2003;143:532-540.
55. Group TI-RS. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998;102:531-537.
56. Carbonell-Estrany X, Simões EA, Dagan R, et al; Motavizumab Study Group. Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a noninferiority trial. Pediatrics. 2010;125:e35-e51.
57. Hasegawa K, Tsugawa Y, Brown DF, et al. Temporal trends in emergency department visits for bronchiolitis in the United States, 2006 to 2010. Pediatr Infect Dis J. 2014;33:11-18.
58. Akenroye AT, Baskin MN, Samnaliev M, et al. Impact of a bronchiolitis guideline on ED resource use and cost: a segmented time-series analysis. Pediatrics. 2014;133:e227-e234.
59. Groothuis JR, Simões EA, Levin MJ, et al. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group. N Engl J Med. 1993;329:1524-1530.
60. Simões EA, Sondheimer HM, Top FH Jr, et al. Respiratory syncytial virus immune globulin for prophylaxis against respiratory syncytial virus disease in infants and children with congenital heart disease. The Cardiac Study Group. J Pediatr. 1998;133:492-499.
61. Behrendt CE, Decker MD, Burch DJ, et al. International variation in the management of infants hospitalized with respiratory syncytial virus. International RSV Study Group. Eur J Pediatr. 1998;157:215-220.
62. Corneli HM, Zorc JJ, Holubkov R, et al; Bronchiolitis Study Group for the Pediatric Emergency Care Applied Research Network. Bronchiolitis: clinical characteristics associated with hospitalization and length of stay. Pediatr Emerg Care. 2012;28:99-103.
63. Halloran ME, Longini IM Jr, Gaglani MJ, et al. Estimating effcacy of trivalent, cold-adapted, infuenza virus vaccine (CAIV-T) against infu-enza A (H1N1) and B using surveillance cultures. Am J Epidemiol. 2003;158:305-311.
64. Piedra PA, Gaglani MJ, Riggs M, et al. Live attenuated infuenza vaccine, trivalent, is safe in healthy children 18 months to 4 years, 5 to 9 years, and 10 to 18 years of age in a community-based, nonrandomized, open-label trial. Pediatrics. 2005;116:e397-e407.
65. Grijalva CG, Zhu Y, Simonsen L, et al. Establishing the baseline burden of infuenza in preparation for the evaluation of a countywide school-based infuenza vaccination campaign. Vaccine. 2010;29:123-129.
66. der Heiden MA, Köpke K, Buda S, et al. Estimates of excess medically attended acute respiratory infections in periods of seasonal and pandemic infuenza in Germany from 2001/02 to 2010/11. PLoS One. 2013;8:e64593.
67. Ambrose CS, Anderson EJ, Simões EA, et al. Respiratory syncytial virus disease in preterm infants in the U.S. born at 32-35 weeks gestation not receiving immunoprophylaxis. Pediatr Infect Dis J. 2014;33:576-582.
68. Simões EA, Ambrose CS, Wu X, et al. Intensive care unit admission rates for respiratory syncytial virus infection as a function of age in preterm infants born at 32-35-week gestation and not receiving immunoprophylaxis. Pediatr Infect Dis J. 2015;34:331.
69. Groothuis JR, Levin MJ, Rodriguez W, et al. Use of intravenous gamma globulin to passively immunize high-risk children against respiratory syncytial virus: safety and pharmacokinetics. The RSVIG Study Group. Antimicrob Agents Chemother. 1991;35:1469-1473.
70. WHO. Acute Respiratory Infection in Children: Case Management in Small Hospitals in Developing Countries-A Manual for Physicians and Other Senior Health Workers. Geneva Switzerland: WHO Division of Diarrheal and Acute Respiratory Disease Control; 1995.
71. WHO. Pocket Book of Hospital Care for Children: Guidelines for the Management of Common Childhood Illnesses. 2nd ed. Geneva, Switzerland: World Health Organization; 2013.
72. Cherian T, John TJ, Simões E, et al. Evaluation of simple clinical signs for the diagnosis of acute lower respiratory tract infection. Lancet. 1988;2:125-128.
73. Simões EA, McGrath EJ. Recognition of pneumonia by primary health care workers in Swaziland with a simple clinical algorithm. Lancet. 1992;340:1502-1503.
74. Mulholland EK, Simões EA, Costales MO, et al. Standardized diagnosis of pneumonia in developing countries. Pediatr Infect Dis J. 1992;11:77-81.
75. Gove S. Integrated management of childhood illness by outpatient health workers: technical basis and overview. The WHO Working Group on Guidelines for Integrated Management of the Sick Child. Bull World Health Organ. 1997;75 (Suppl 1):7-24.
76. Simões EA, Desta T, Tessema T, et al. Performance of health workers after training in integrated management of childhood illness in Gondar, Ethiopia. Bull World Health Organ. 1997;75 (Suppl 1):43-53.
77. Nagasaka Y. Lung sounds in bronchial asthma. Allergol Int. 2012;61:353-363.
78. Greenough A, Alexander J, Burgess S, et al. Health care utilisation of prematurely born, preschool children related to hospitalisation for RSV infection. Arch Dis Child. 2004;89:673-678.
79. Bont L, Steijn M, van Aalderen WM, et al. Impact of wheezing after respiratory syncytial virus infection on health-related quality of life. Pediatr Infect Dis J. 2004;23:414-417.
80. Stensballe LG, Kristensen K, Simões EA, et al; Danish RSV Data Network. Atopic disposition, wheezing, and subsequent respiratory syncytial virus hospitalization in Danish children younger than 18 months: a nested case-control study. Pediatrics. 2006;118:e1360-e1368.
81. Sherriff A, Peters TJ, Henderson J, et al; ALSPAC Study Team. Avon Longitudinal Study of Parents and Children. Risk factor associations with wheezing patterns in children followed longitudinally from birth to 3(1/2) years. Int J Epidemiol. 2001;30:1473-1484.
82. Lemanske RF Jr. The childhood origins of asthma (COAST) study. Pediatr Allergy Immunol. 2002;13 (Suppl 15):38-43.
83. Jamison DT. Investing in health. In: Jamison DT, Breman JG, Measham AR, et al, eds. Disease Control Priorities in Developing Countries. 2nd ed. Washington, DC: World Bank; 2006.